Monalizumab

Cat. No.: IBDI-431988

Monalizumab is a first-in-class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Product Details

Target	Checkpoint Kinase (Chk) | IFNAR
Appearance	Liquid
SMILES	[Monalizumab]
Purity	99.69%

Storage & Handling

Shipping	Shipping with dry ice.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.